Drug Profile
Research programme: CNS therapeutics - Ms Science
Alternative Names: MC-116Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Ms Science
- Class Neuroprotectants
- Mechanism of Action Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 29 Aug 2023 Preclinical development is ongoing in CNS disorders in Japan (Ms Science website, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in CNS-disorders in Japan
- 21 Jan 2016 Preclinical trials in CNS disorders in Japan (unspecified route) before January 2016